A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
Identifieur interne : 003521 ( Main/Exploration ); précédent : 003520; suivant : 003522A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
Auteurs : Kai Schulze [Allemagne] ; Caroline Staib [Allemagne] ; Hermann M. Sch Tzl [Allemagne] ; Thomas Ebensen [Allemagne] ; Volker Erfle [Allemagne] ; Carlos A. Guzman [Allemagne]Source :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques, Administration par voie nasale, Animaux, Anticorps antiviraux (immunologie), Immunité cellulaire, Immunoglobuline A (immunologie), Injections musculaires, Lipopeptides (immunologie), Protéines nucléocapside (immunologie), Rappel de vaccin (), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Virus de la vaccine (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- immunologie : Anticorps antiviraux, Immunoglobuline A, Lipopeptides, Protéines nucléocapside, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus de la vaccine, Virus du SRAS.
- Pascal (Inist)
- Adjuvants immunologiques, Administration par voie nasale, Animaux, Immunité cellulaire, Injections musculaires, Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Virus syndrome respiratoire aigu sévère, Virus vaccine, Vaccination, Réponse immune, Nucléocapside, Protéine, Adjuvant immunologique, Muqueuse, Immunisation, Vaccin.
- Wicri :
- topic : Vaccination, Vaccin.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Administration, Intranasal, Animals, Antibodies, Viral (immunology), Immune response, Immunity, Cellular, Immunization, Immunization, Secondary (methods), Immunoglobulin A (immunology), Immunological adjuvant, Injections, Intramuscular, Lipopeptides (immunology), Mice, Mice, Inbred BALB C, Mucosa, Nucleocapsid, Nucleocapsid Proteins (immunology), Protein, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe acute respiratory syndrome virus, Vaccination, Vaccine, Vaccinia virus, Vaccinia virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Immunoglobulin A, Lipopeptides, Nucleocapsid Proteins, Viral Vaccines.
- chemical : Adjuvants, Immunologic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vaccinia virus.
- methods : Immunization, Secondary.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Immunity, Cellular, Injections, Intramuscular, Mice, Mice, Inbred BALB C.
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000239
- to stream PascalFrancis, to step Curation: 000749
- to stream PascalFrancis, to step Checkpoint: 000301
- to stream Main, to step Merge: 003627
- to stream Pmc, to step Corpus: 001540
- to stream Pmc, to step Curation: 001540
- to stream Pmc, to step Checkpoint: 000E57
- to stream PubMed, to step Corpus: 001A64
- to stream PubMed, to step Curation: 001A64
- to stream PubMed, to step Checkpoint: 001C03
- to stream Ncbi, to step Merge: 001D52
- to stream Ncbi, to step Curation: 001D52
- to stream Ncbi, to step Checkpoint: 001D52
- to stream Main, to step Merge: 003271
- to stream Main, to step Curation: 003521
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title><author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>German Center for Environmental Health</wicri:noRegion><wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion></affiliation></author><author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation></author><author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author><author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>German Center for Environmental Health</wicri:noRegion><wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion></affiliation></author><author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0039741</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 09-0039741 INIST</idno><idno type="RBID">Pascal:09-0039741</idno><idno type="wicri:Area/PascalFrancis/Corpus">000239</idno><idno type="wicri:Area/PascalFrancis/Curation">000749</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000301</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000301</idno><idno type="wicri:doubleKey">0264-410X:2008:Schulze K:a:prime:boost</idno><idno type="wicri:Area/Main/Merge">003627</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115531</idno><idno type="RBID">PMC:7115531</idno><idno type="wicri:Area/Pmc/Corpus">001540</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001540</idno><idno type="wicri:Area/Pmc/Curation">001540</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001540</idno><idno type="wicri:Area/Pmc/Checkpoint">000E57</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E57</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18805454</idno><idno type="wicri:Area/PubMed/Corpus">001A64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A64</idno><idno type="wicri:Area/PubMed/Curation">001A64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A64</idno><idno type="wicri:Area/PubMed/Checkpoint">001C03</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C03</idno><idno type="wicri:Area/Ncbi/Merge">001D52</idno><idno type="wicri:Area/Ncbi/Curation">001D52</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D52</idno><idno type="wicri:doubleKey">0264-410X:2008:Schulze K:a:prime:boost</idno><idno type="wicri:Area/Main/Merge">003271</idno><idno type="wicri:Area/Main/Curation">003521</idno><idno type="wicri:Area/Main/Exploration">003521</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title><author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>German Center for Environmental Health</wicri:noRegion><wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion></affiliation></author><author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation></author><author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author><author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Technical University Munich</wicri:noRegion><wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1><s3>DEU</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>German Center for Environmental Health</wicri:noRegion><wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion></affiliation></author><author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1><s2>38124 Braunschweig</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>38124 Braunschweig</wicri:noRegion><wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion><wicri:noRegion>38124 Braunschweig</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Immune response</term><term>Immunity, Cellular</term><term>Immunization</term><term>Immunization, Secondary (methods)</term><term>Immunoglobulin A (immunology)</term><term>Immunological adjuvant</term><term>Injections, Intramuscular</term><term>Lipopeptides (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mucosa</term><term>Nucleocapsid</term><term>Nucleocapsid Proteins (immunology)</term><term>Protein</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe acute respiratory syndrome virus</term><term>Vaccination</term><term>Vaccine</term><term>Vaccinia virus</term><term>Vaccinia virus (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Immunité cellulaire</term><term>Immunoglobuline A (immunologie)</term><term>Injections musculaires</term><term>Lipopeptides (immunologie)</term><term>Protéines nucléocapside (immunologie)</term><term>Rappel de vaccin ()</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus de la vaccine (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin A</term><term>Lipopeptides</term><term>Nucleocapsid Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline A</term><term>Lipopeptides</term><term>Protéines nucléocapside</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus de la vaccine</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccinia virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Immunity, Cellular</term><term>Injections, Intramuscular</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Administration par voie nasale</term><term>Animaux</term><term>Immunité cellulaire</term><term>Injections musculaires</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Virus syndrome respiratoire aigu sévère</term><term>Virus vaccine</term><term>Vaccination</term><term>Réponse immune</term><term>Nucléocapside</term><term>Protéine</term><term>Adjuvant immunologique</term><term>Muqueuse</term><term>Immunisation</term><term>Vaccin</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccination</term><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name></noRegion><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003521 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003521 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0039741
|texte= A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |